Cover Image
市場調查報告書

全球亨丁頓舞蹈症治療藥市場未來趨勢

Global Huntington's Disease Therapeutics Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317294
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
全球亨丁頓舞蹈症治療藥市場未來趨勢 Global Huntington's Disease Therapeutics Market 2014-2018
出版日期: 2014年10月22日 內容資訊: 英文 72 Pages
簡介

亨丁頓舞蹈症是進行性的神經退化性疾病,由於有體染色體顯性特質,有從1代傳到下1代世代遺傳可能性。這個疾病,是腦的一部分(大腦基底核、大腦皮質等)的神經細胞產生遺傳性編程變形而發病。大腦基底核具有運動調整重要功能,另一方面,大腦皮質掌管認識、思考、記憶。由於神經細胞變形,使認知障礙階段性地進行。還有亨丁頓舞蹈症的患者,常常舞蹈病也會(手、臉、軀體、腳的肌肉的不隨意運動)發病。這個疾病伴隨的行動障礙,有憂鬱症和精神障礙、人格的變化等。其他也會呈現語言障礙和焦慮症、緊張狀態、吞嚥障礙的症狀。亨丁頓舞蹈症的患者,通常30∼40多歲發病,不過,極少數情況下也有在幼兒期和少年期發病。前者稱為成人發病型,後者稱為早期發病型,不過,早期發病型和其他症狀(震顫、行動慢、身體僵直等)有相關性。早期發病型的患者很少能活到成人。現在,尚未找到亨丁頓舞蹈症的有效治療方法。全球亨丁頓舞蹈症治療藥市場2013∼2018年的年複合成長率(CAGR)預計達到29.46%。

本報告提供全球的亨丁頓舞蹈症治療藥的市場相關分析、市場概要和結構、市場規模趨勢(今後5年的預測值)、各藥物等級、各地區的詳細趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查、考察。

第1章 摘要整理

第2章 簡稱集

第3章 分析範圍

  • 市場概要
  • 主要的產品

第4章 市場分析技術

  • 市場分析的流程
  • 分析方法

第5章 簡介

第6章 亨丁頓舞蹈症的患病人數

第7章 市場環境

  • 市場概況
  • 市場規模與其預測
  • 波特的五力分析

第8章 各藥物等級的市場分析

第9章 各地區的分析

第10章 購買標準

第11章 促進市場成長的要素

第12章 推動因素與其影響力

第13章 市場課題

第14章 推動因素、課題的影響力

第15章 市場趨勢

第16章 市場趨勢與其影響

第17章 供應商環境

  • 競爭方案
    • 近幾年的主要趨勢
  • 市場佔有率分析
  • 未來的有力供應商

第18章 臨床實驗階段的開發平台候補藥

第19章 臨床實驗階段的開發平台候補藥的主要資料

  • SD-809ER
  • RP103
  • ABR-215062
  • BN82451
  • OMS824
  • PF-02545920
  • SEN0014196
  • TV-7820
  • PBT2
  • GSK356278
  • PBF-999

第20章 臨床實驗中止的開發平台醫藥品

第21章 主要供應商分析

  • H. Lundbeck
    • 主要資料
    • 產業概要
    • 各部門的市場收益額(最新價值)
    • 各部門的市場收益額(與前年度的比較)
    • 各地區的市場收益額
    • 產業策略
    • 近幾年趨勢
    • SWOT分析
  • Valeant Pharmaceuticals International

第22章 其他相關分析

圖表一覽

目錄
Product Code: IRTNTR4355

About Huntington's Disease

Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. People with Huntington's disease often develop chorea that causes involuntary muscle movements of hands, face, trunk, and feet. The behavioural disorders associated with the disease include depression, psychosis, and changes in personality. Other symptoms of the disease include speech impairment, anxiety, stress, and difficulty in swallowing. People suffering from Huntington's disease usually develop symptoms in their mid-30s and 40s. However, in few cases, disease symptoms appear in childhood or teens. The former case represents the adult-onset form of the disease, while the latter is the early-onset form. The early-onset form is associated with symptoms such as tremors, slow movements, and rigidity. Children with early-onset disease rarely live to adulthood. Currently, there is no approved treatment for Huntington's disease.

TechNavio's analysts forecast the Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Huntington's Disease Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of symptoms of Huntington's disease.

TechNavio's report, the Global Huntington's Disease Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Huntington's Disease Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Lundbeck
  • Valeant Pharmaceuticals International

Other Prominent Vendors

  • Auspex Pharmaceuticals
  • GlaxoSmithKline
  • Ipsen
  • Omeros
  • Palobiofarma
  • Pfizer
  • Prana Biotechnology
  • Raptor Pharmaceutical
  • Siena Biotech
  • SOM Biotech
  • Teva Pharmaceutical Industries

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Poor Diagnosis Rates
  • For a full, detailed list, view our report

Market Trend

  • Novel Mechanisms Targeted by Pipeline Candidates
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Prevalence of Huntington's Disease

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Drug Class

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
  • 17.2. Market Share Analysis 2013
  • 17.3. Potential Future Vendors

18. Clinical-stage Pipeline Candidates

19. Key Information of Clinical-stage Pipeline Candidates

  • 19.1. SD-809ER
  • 19.2. RP103
  • 19.3. ABR-215062
  • 19.4. BN82451
  • 19.5. OMS824
  • 19.6. PF-02545920
  • 19.7. SEN0014196
  • 19.8. TV-7820
  • 19.9. PBT2
  • 19.10. GSK356278
  • 19.11. PBF-999

20. Discontinued Clinical-stage Pipeline Drugs

21. Key Vendor Analysis

  • 21.1. H. Lundbeck
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Product Segmentation by Revenue 2013
    • 21.1.4. Product Segmentation by Revenue 2012 and 2013
    • 21.1.5. Geographical Segmentation by Revenue 2013
    • 21.1.6. Business Strategy
    • 21.1.7. Recent Developments
    • 21.1.8. SWOT Analysis
  • 21.2. Valeant Pharmaceuticals International
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation by Revenue 2013
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Business Strategy
    • 21.2.7. Key Developments
    • 21.2.8. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Prevalence of Huntington's Disease by Geography 2013
  • Exhibit 3: Global Huntington's Disease Therapeutics Market 2013-2018 (US$ million)
  • Exhibit 4: Global Huntington's Disease Therapeutics Market by Drug Class
  • Exhibit 5: Global Huntington's Disease Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 6: Global Huntington's Disease Therapeutics Market Share Analysis 2013
  • Exhibit 7: Key Regulatory Approvals of Tetrabenazine
  • Exhibit 8: Key Events of Xenazine
  • Exhibit 9: Valeant Pharmaceuticals International Inc.: Sales of Xenazine 2008-2013 (US$ million)
  • Exhibit 10: Valeant Pharmaceuticals International Inc.: Sales of Xenazine by Geography 2013
  • Exhibit 11: H. Lundbeck A/S: Sales of Xenazine 2009-2013 (US$ million)
  • Exhibit 12: H. Lundbeck A/S: Quaterly Sales of Xenazine 2009-2013 (US$ million)
  • Exhibit 13: H. Lundbeck: Business Segmentation by Revenue 2013
  • Exhibit 14: H. Lundbeck: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 15: H. Lundbeck: Geographical Segmentation by Revenue 2013
  • Exhibit 16: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2013
  • Exhibit 17: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 18: Valeant Pharmaceuticals International Inc.: Sales by Geography 2013
Back to Top